ArticleProtein & cell2026
Systematic analyses uncover plasma proteins linked to incident cardiovascular diseases.
Article in Protein & cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Proteomic Mendelian randomization and machine learning reveal causal plasma biomarkers in cardiorenal comorbidity.Renal failure · 2026Article
- Proteomics of multimorbidity progression across cardiometabolic diseases and cancer in a multinational cohort.Cardiovascular diabetology · 2026Article
- The Roles of EDA2R in Ageing and Disease.Aging cell · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Cardiovascular disease (CVD) research is hindered by limited comprehensive analyses of plasma proteome across disease subtypes. Here, we systematically investigated the associations between plasma proteins and cardiovascular outcomes in 53,026 UK Biobank participants over a 14-year follow-up. Association analyses identified 3,089 significant associations involving 892 unique protein analytes across 13 CVD outcomes. The most notable associations included NT-proBNP for atrial fibrillation (P = 6.31 × 10-313), followed by NPPB (P = 1.03 × 10-164) and GDF15 for heart failure (P = 1.21 × 10-166). Among 445 unique proteins significantly linked to 18 cardiovascular metrics, LEP (RVEDV: β = -9.03, P = 2.76 × 10-51) and FABP4 (RVEDV: β = -10.18, P = 2.42 × 10-32) emerged as the strongest correlates of cardiac structure and function. Our integrated prediction model performed excellently across the majority of CVD outcomes, achieving an AUC of 0.86 for abdominal aneurysm. Two-sample Mendelian randomization analysis revealed 225 proteins causally linked to CVDs, with LPA showing the strongest coronary artery disease association (OR = 1.13 [1.10-1.17], P = 2.38 × 10-15), many of which are targets of existing drugs, suggesting repurposing opportunities. Mediation analysis revealed broad-spectrum mediators (e.g., IGFBP4 and GDF15, each influencing 9 cardiovascular outcomes) and outcome-specific protein mediators, with modifiable risk factors such as smoking and BMI predominantly mediating protein-CVD associations.This comprehensive longitudinal study provides unprecedented insights into plasma proteome influences on cardiovascular health interactions, offering novel perspectives for CVD diagnosis, prediction, and prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.